• Publicaciones científicas destacadas

  • Marzo 2008

    Intravitreal bevacizumab (Avastin) for choroidal neovascularization secondary to pathological myopia: 6-month results L. Arias, N. Planas, S. Prades, J. M. Caminal, M. Rubio, O. Pujol, G. Roca. Br. J. Ophthalmol. 2008;92;1035-1039

    Ver artículo

  • Enero 2008

    Delay in treating age-related macular degeneration in Spain is associated with progressive vision lossConclussions Delayed treatment of patients newly diagnosed with NV-AMD is associated with substantial visual acuity loss. doi:10.1038

    Ver artículo

  • Octubre 2007

    Management of diabetic macular edema with antiangiogenic therapyEvaluation of: Chun DW. Heier JS. Topping TM, Duker JS, Bankert JM. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology 113, 1706-1712.

    Ver artículo

  • Septiembre 2007

    Soubrane G, Cruess A, Lotery A, Pauleikhoff D, Mones J, Xu X, Zlateva G, Buggage R, Conlon J, Goss TF..Burden and health care resource utilization in neovascular age-related macular degeneration: findings of a multicountry study. Arch Ophthalmol. ;125(9):1249-54.

    Ver artículo

  • Septiembre 2007

    Monés J [Bevacizumab or Ranibizumab, or the tale of Robin Hood and King Richard Lion Heart.]Arch Soc Esp Oftalmol.;82(9):529-30. Spanish. No abstract available. PMID: 17846939 PubMed - in process.

    Ver artículo

  • Mayo-Junio 2007

    Mones JM, Lopez MA, Prieto JA, Rodriguez JP.Extrafoveal choroidal neovascularization secondary to wet age-related macular degeneration treated with intravitreal bevacizumab.Ophthalmic Surg Lasers Imaging. ;38(3):226-8.

    Ver artículo

  • Septiembre 2006

    Chakravarthy U, Soubrane G, Bandello F, Chong V, Creuzot-Garcher C,Dimitrakos SA 2nd, Korobelnik JF, Larsen M, Mones J, Pauleikhoff D, PournarasCJ, Staurenghi G, Virgili G, Wolf S. Evolving European guidance on the medical management of neovascular age related macular degeneration.Br J Ophthalmol. ;90(9):1188-96.

    Ver artículo

  • Noviembre 2005

    2: Mones J. New perspectives on the treatment of age-related macular degeneration. Drugs Today (Barc).;41(11):701.

    Ver artículo

  • 2005

    ( Jordi Monés as in TAP Study Group ) Verteporfin Therapy for Subfoveal Choroidal Neovascularization in Age-Related Macular Degeneration: Four-Year Results of an Open-Label Extension of 2 Randomized Clinical Trials: TAP Report No. 7 Arch Ophthalmol. ;123:1283-1285.

    Ver artículo

  • Diciembre 2004

    ( Jordi Monés as in the Writing Committee ) Pegaptanib for Neovascular Age-Related Macular Degeneration. Evangelos S. Gragoudas, M.D., Anthony P. Adamis, M.D.,Emmett T. Cunningham, Jr., M.D., Ph.D., M.P.H., Matthew Feinsod, M.D.,and David R. Guyer, M.D., for the VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. n engl j med 351;27 www.nejm.org.

  • Octubre 2004

    Monés J, Rubin GS. Contrast sensitivity as an outcome measure in patients with subfoveal choroidal neovascularisation due to age-related macular degeneration.Eye.

    Ver artículo

  • Febrero 2004

    Azab M, et al. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials: Treatment Of Age-Related Macular Degeneration With Photodynamic Therapy and Verteporfin In Photodynamic Therapy Study Report no. 4. Retina. ;24(1):1-12.

    Ver artículo

  • Septiembre 2003

    TAP Study Group. ( Jordi Monés as is the writing Committee ). Blinder KJ, et al; Treatment of Age-related Macular Degeneration with Photodynamic Therapy study group; Verteporfin in Photodynamic Therapy study group. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. Am J Ophthalmol. ;136(3):407-18

  • Abril 2003

    Blinder KJ, et al Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial--VIP report no. 3. Ophthalmology. ;110(4):667-73.